viaskin peanut - search results

If you're not happy with the results, please do another search

Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA Approval

The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.

Viaskin Peanut Patch: Lasting Response After Three Years

Pediatric patients responded with a favorable safety profile and no serious adverse effects.

Viaskin Peanut, Milk and Egg Patch Therapies: Promising News from the AAAAI Conference

We are cautiously optimistic that a safe, effective, easy to administer treatment for food allergy may be on the horizon.
Viaskin Patch

Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon? The Company is...

Company is restructuring in anticipation of delays.

Viaskin Patch Delivers Long-Lasting Peanut Desensitization After Phase IIb Trial

The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.
FARE Reponse to ICER Report

Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies

FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
AAFA Reponse to ICER Report

Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut...

The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.
ICER Final Report

ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That...

The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
AAFA Press Release Regarding ICER Review

Asthma and Allergy Foundation of America Elevates Patient Voice in ICER Review of New...

Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
FARE-ACAAI-AAN Statement

Joint Statement on Peanut Allergy Therapy Review

Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.